SCHEDULE 13G/A: Point72 and Steven Cohen Disclose Significant Passive Stake in Alto Neuroscience

Point72 Asset Management and its affiliates, along with Steven A. Cohen, have disclosed an aggregate beneficial ownership of 8.8% in Alto Neuroscience, Inc. as of December 31, 2024, through a Schedule 13G filing.

Summary

• Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. each reported shared beneficial ownership of 1,692,153 shares of Alto Neuroscience, Inc. Common Stock, representing 6.3% of the class.
• Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, and 72 Investment Holdings, LLC each reported shared beneficial ownership of 667,778 shares, representing 2.5% of the class.
• Steven A. Cohen, who controls the aforementioned entities, reported an aggregate shared beneficial ownership of 2,359,931 shares, equating to 8.8% of Alto Neuroscience's Common Stock.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing or an initial filing for the specified period.
• The ownership is reported as of the close of business on December 31, 2024.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Alto Neuroscience, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory disclosure of beneficial ownership, providing factual information without expressing positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing reflects a significant passive investment by a prominent hedge fund manager and his affiliated entities in a biotechnology company. Such disclosures are standard for institutional investors crossing certain ownership thresholds and provide transparency into major shareholder positions within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing market perception and trading activity due to the involvement of a notable investor like Steven A. Cohen and Point72.

Key Dates

Keywords

Alto Neuroscience, Point72 Asset Management, Steven A. Cohen, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Passive Investment